ArticleCancer cell2020
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 308 papers.
0numbers the graph read from it
0cells of the map it votes in
308citing papers in PubMed
22.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
308 citing papers in PubMed, 444 citations in OpenAlex.
- Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.Nature communications · 2026Trial
- Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.Nature communications · 2024Trial
- Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.Scientific reports · 2023Trial
- Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer.Cancer biology & therapy · 2026Review
- Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Dendritic Cell Dysfunction Underlies Immune Escape After Adoptive Cellular Therapy in Glioblastoma.Cancers · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer.Cancer immunology research · 2026Article
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Engineered probioticScience advances · 2026Article
- Breaking barriers: nano-boosted drug delivery systems in overcoming the defenses of pancreatic cancer.Molecular cancer · 2026Review
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case Report and Literature Review.International journal of molecular sciences · 2026Review
- DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation.The Journal of clinical investigation · 2026Article
- Murine osteosarcoma recapitulates the driver landscape and genomic complexity of osteosarcoma evolution in humans.bioRxiv : the preprint server for biology · 2026Article
- Tailoring Vascular-Immune Homeostasis via Manganese-DNA Complex-Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.Journal for immunotherapy of cancer · 2026Article
248 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Samarth HegdeDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Varintra E KrisnawanDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Brett H HerzogDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Chong ZuoDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Marcus A BredenDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Brett L KnolhoffDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Graham D HoggDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jack P TangDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
John M BaerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cedric MpoyDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Kyung Bae LeeDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Katherine A AlexanderDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Buck E RogersDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA.
Kenneth M MurphyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110, USA.
William G HawkinsDepartment of Surgery, Barnes-Jewish Hospital, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA.
Ryan C FieldsDepartment of Surgery, Barnes-Jewish Hospital, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA.
Carl J DeSelmDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA.
Julie K SchwarzDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA.
David G DeNardoDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Alvin J. Siteman Comprehensive Cancer Center, St. Louis, MO 63110, USA. Electronic address: ddenardo@wustl.edu.
Washington University in St. Louis · USBarnes-Jewish Hospital · USHoward Hughes Medical Institute · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4MWashington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9MOptimizing radiation therapy through the manipulation of glutamine metabolismR01CA181745 · NCI · WASHINGTON UNIVERSITY · PI SCHWARZ, JULIE KRISTINA · 2014 to 2025
$3.4MThe Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic CancerR01CA177670 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G · 2014 to 2023
$3.3MExploiting Integrin Signaling to Overcome Resistance to ImmunotherapyR01CA244938 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G, GUPTA, VINEET · 2020 to 2024
$2.2MImmune Activating CAR-Modified Antigen Presenting CellsDP5OD026427 · OD · WASHINGTON UNIVERSITY · PI DESELM, CARL · 2018 to 2022
$2.0MCOMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPYR01CA203890 · NCI · WASHINGTON UNIVERSITY · PI DENARDO, DAVID G · 2016 to 2020
$1.7MPURCHASE OF AN IMAGE-GUIDED SMALL-ANIMAL IRRADIATORS10OD020136 · OD · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2015 to 2015
$600kDefining the barriers to immune surveillance in solid tumorsK00CA223043 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEGDE, SAMARTH · 2020 to 2023
$374kNCATS NIH HHS UL1 TR002345NCI NIH HHS F99 CA223043NCI NIH HHS K00 CA223043NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA177670NCI NIH HHS R01 CA181745NCI NIH HHS R01 CA203890NCI NIH HHS R01 CA244938NCRR NIH HHS UL1 RR024992NIDDK NIH HHS P30 DK052574NIH HHS DP5 OD026427NIH HHS S10 OD020136
Abstract
Here, we utilized spontaneous models of pancreatic and lung cancer to examine how neoantigenicity shapes tumor immunity and progression. As expected, neoantigen expression during lung adenocarcinoma development leads to T cell-mediated immunity and disease restraint. By contrast, neoantigen expression in pancreatic ductal adenocarcinoma (PDAC) results in exacerbation of a fibro-inflammatory microenvironment that drives disease progression and metastasis. Pathogenic T
Indexed as
Adenocarcinoma of LungAnimalsCarcinoma, Pancreatic DuctalCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsHumansImmunotherapyLung NeoplasmsMiceMice, Inbred C57BLMice, Mutant StrainsMice, TransgenicPancreatic NeoplasmsCD40dendritic cellFlt3Limmune surveillanceimmunotherapyneoantigenpancreatic cancerradiation therapyvaccination
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.